
    
      This is a phase 1 first-in-human clinical trial to assess the safety, tolerability, and
      immunogenicity of eOD-GT8 60mer Vaccine, Adjuvanted, in up to 48 healthy adult HIV-negative
      volunteers. The study is a randomized, double-blind, placebo-controlled dosage-escalation
      Phase 1 study intended to evaluate the safety and immunogenicity of eOD-GT8 60mer Vaccine,
      Adjuvanted in a prime-boost regimen.
    
  